;
Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: AbbVie, Shire abandon the altar

    AbbVie Inc. (NYSE:ABBV) and Shire plc (LSE:SHP; NASDAQ:SHPG) on Monday agreed to terminate their proposed acquisition, less than a week after the pharma said it was reconsidering the deal. AbbVie must now pay Shire a $…

    Published on 10/20/2014
  • COMPANY NEWS: FDA panel backs Novartis' secukinumab for psoriasis

    FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 7-0 to recommend approval of Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat moderate to severe plaque psoriasis in adults who are …

    Published on 10/20/2014
  • COMPANY NEWS: Taiho put on Fast Track in mCRC

    The Taiho Oncology Inc. subsidiary of Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) said FDA has granted Fast Track designation for its TAS-102 to treat refractory metastatic colorectal cancer (mCRC) and that the …

    Published on 10/20/2014
  • COMPANY NEWS: Astellas, CoMentis end AD collaboration

    Astellas Pharma Inc. (Tokyo:4503) and CoMentis Inc. (South San Francisco, Calif.) terminated a 2008 deal to develop and commercialize beta-secretase (BACE1) inhibitors to treat Alzheimer's disease (AD). Astellas, which…

    Published on 10/17/2014
  • COMPANY NEWS: EC approves Imbruvica for CLL, MCL

    The European Commission has approved Imbruvica ibrutinib from Pharmacyclics Inc. (NASDAQ:PCYC) and the Janssen-Cilag International NV unit of Johnson & Johnson (NYSE:JNJ) to treat patients with mantle cell lymphoma (…

    Published on 10/17/2014
  • COMPANY NEWS: FDA approves abuse-deterrent labeling for Embeda

    FDA approved expanded labeling for Embeda morphine sulfate/naltrexone hydrochloride extended-release capsules from Pfizer Inc. (NYSE:PFE) to include data from abuse-deterrent studies. Embeda is indicated to treat …

    Published on 10/17/2014
  • COMPANY NEWS: FDA reviewers: some R117H CF patients get Kalydeco benefit

    FDA reviewers said "at least some CF patients with a R117H mutation" in the cystic fibrosis transmembrane conductance regulator (CFTR) gene benefit from Kalydeco ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:…

    Published on 10/17/2014
  • COMPANY NEWS: NICE now recommends adjuvant Glivec

    The U.K.'s NICE proposed to recommend Glivec imatinib from Novartis AG (NYSE:NVS; SIX:NOVN) as adjuvant treatment for up to three years in adult patients at high-risk for tumor recurrence following complete surgical …

    Published on 10/17/2014
  • COMPANY NEWS: VC tracks

    Canaan Partners promoted Tim Shannon to general partner and Julie Papanek to principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp. through its sale to Celldex …

    Published on 10/17/2014
  • COMPANY NEWS: Aduro, J&J in second cancer pact

    Immunotherapy specialist Aduro BioTech Inc. (Berkeley, Calif.) entered into its second licensing agreement with the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE: JNJ). The biotech granted Janssen …

    Published on 10/16/2014
  • COMPANY NEWS: FDA reviewers back Novartis' psoriasis mAb

    FDA reviewers said "available data support a favorable benefit-risk assessment" for Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat moderate to severe plaque psoriasis in adults who are candidates …

    Published on 10/16/2014
  • COMPANY NEWS: Immune Design boosted by compound pooling deal with Sanofi

    Immune Design Corp. (NASDAQ:IMDZ) added $2.22 (11%) to $23.23 on Thursday after it announced a deal with Sanofi (Euronext:SAN; NYSE:SNY) to pool compounds in a discovery and development deal focused on immune therapies…

    Published on 10/16/2014
  • COMPANY NEWS: Regeneron Genetics Center adds 3 academic deals

    The Regeneron Genetics Center LLC (RGC) of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) expanded its footprint with three new partnerships with academic research centers and the formation a scientific advisory board. …

    Published on 10/16/2014
  • COMPANY NEWS: Shire stabilizes as investors look past AbbVie

    Shares of Shire plc plc (LSE:SHP; NASDAQ:SHPG) added $7.97 to $178.46 on NASDAQ on Thursday as investors mulled the company's prospects after the board of AbbVie Inc. (NYSE:ABBV) recommended that stockholders vote …

    Published on 10/16/2014
  • COMPANY NEWS: AbbVie reconsidering Shire acquisition

    Shire plc (LSE:SHP; NASDAQ:SHPG) plunged $74.08 (30%) to $170.49 on NASDAQ on Wednesday after AbbVie Inc. (NYSE:ABBV) said it will reconsider the companies' planned merger. Shire is off $22 (11%) from its June 19 close…

    Published on 10/15/2014
  • COMPANY NEWS: Chimerix gives update on brincidofovir, CMX16669

    Chimerix Inc. (NASDAQ:CMRX) announced next steps for development of brincidofovir to treat Ebola and other viral infections in an R&D update. The company also plans to file an IND for CMX16669 to treat cytomegalovirus (…

    Published on 10/15/2014
  • COMPANY NEWS: Orexigen ships Contrave; head-on pricing set

    Orexigen Therapeutics Inc. (NASDAQ:OREX) said it received a $70 million milestone payment from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) after it sent the first shipment of obesity drug Contrave naltrexone/bupropion…

    Published on 10/15/2014
  • COMPANY NEWS: J&J offers Olysio cost-sharing in Scotland

    The Scottish Medicines Consortium recommended Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ) in combination with other therapies to treat chronic HCV genotypes 1 and 4 infection in …

    Published on 10/14/2014
  • COMPANY NEWS: NICE spurns Celgene's Imnovid for MM

    The U.K.'s NICE issued draft guidance recommending against use of Imnovid pomalidomide from Celgene Corp. (NASDAQ:CELG) in combination with dexamethasone to treat relapsed and refractory multiple myeloma (MM). The …

    Published on 10/14/2014
  • COMPANY NEWS: Priority Reviews for Eisai's lenvatinib and rufinamide

    Eisai Co. Ltd. (Tokyo:4523) said FDA accepted for filing and granted Priority Review to an NDA for lenvatinib (E7080) and an sNDA for rufinamide (E2080). Eisai is seeking approval of lenvatinib to treat progressive, …

    Published on 10/14/2014
  • COMPANY NEWS: BMS, Pharmacyclics to test Opdivo/Imbruvica combo

    Bristol-Myers Squibb Co. (NYSE:BMY) partnered with Pharmacyclics Inc. (NASDAQ:PCYC) and Johnson & Johnson (NYSE:JNJ) to evaluate BMS's Opdivo nivolumab in combination with Imbruvica ibrutinib in a Phase I/II trial to…

    Published on 10/13/2014
  • COMPANY NEWS: Priority Review for Pfizer's palbociclib

    Pfizer Inc. (NYSE:PFE) said FDA accepted for filing and granted Priority Review to an NDA for palbociclib in combination with Femara letrozole as first-line treatment for postmenopausal women with estrogen receptor-…

    Published on 10/13/2014
  • COMPANY NEWS: Exact up on Cologuard reimbursement

    Exact Sciences Corp. (NASDAQ:EXAS) jumped $6.48 (36%) to $24.60 on Friday, adding $537.4 million in market cap to $2 billion, on news CMS has proposed reimbursement of $502 for Cologuard, the company's non-invasive DNA…

    Published on 10/10/2014
  • COMPANY NEWS: FDA approves Helsinn's Akynzeo combo for CINV

    FDA approved Akynzeo netupitant/palonosetron from Helsinn Healthcare S.A. (Lugano, Switzerland) to treat chemotherapy-induced nausea and vomiting (CINV).Akynzeo, previously known as NEPA, is a fixed-dose combination of …

    Published on 10/10/2014
  • COMPANY NEWS: Management tracks

    Roth Capital Partners named John Chambers vice-chairman. Chambers, who joined ROTH in 2009, remains head of its healthcare investment banking group. He was previously the head of the healthcare and investment banking …

    Published on 10/10/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993